Browsing Tag

PRNewswire

53973 posts
GMM Music Announces Strategic Partnership with Tencent Music Entertainment Group and Tencent, with a Strategic Investment Valuing GMM Music at 0 Million USD

GMM Music Announces Strategic Partnership with Tencent Music Entertainment Group and Tencent, with a Strategic Investment Valuing GMM Music at $700 Million USD

BANGKOK, June 3, 2024 /PRNewswire/ — GMM Music today announced a strategic…
ATxSG2024: Sunwave Highlights Wireless and Satellite Innovations

ATxSG2024: Sunwave Highlights Wireless and Satellite Innovations

SINGAPORE, June 3, 2024 /PRNewswire/ — During ATxSG 2024 from May 29th…
Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab as Neoadjuvant Treatment of Colon Cancer at 2024 ASCO Annual Meeting

Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab as Neoadjuvant Treatment of Colon Cancer at 2024 ASCO Annual Meeting

SAN FRANCISCO and SUZHOU, China, June 3, 2024 /PRNewswire/ — Innovent Biologics,…
Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment of Advanced Pancreatic Cancer and Gastric Cancer

Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment of Advanced Pancreatic Cancer and Gastric Cancer

SAN FRANCISCO and SUZHOU, China, June 3, 2024 /PRNewswire/ — Innovent Biologics, Inc. ("Innovent")…
China Medical University Hospital (CMUH, Taiwan) Signs MOU with Malaysian International Medical University

China Medical University Hospital (CMUH, Taiwan) Signs MOU with Malaysian International Medical University

Wistron and imedtac jointly promote leading medical products with CMUH in Malaysia…
Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis

Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis

CHENGDU, China, June 3, 2024 /PRNewswire/ — Keymed Biosciences Inc. (HKEX: 02162)…
Thrive with GBA | The Bay to Bay Dialogue held to deepen mutual understanding between China and US

Thrive with GBA | The Bay to Bay Dialogue held to deepen mutual understanding between China and US

GUANGZHOU, China, June 3, 2024 /PRNewswire/ — A news report from GDToday:  jwplayer.key=”3Fznr2BGJZtpwZmA+81lm048ks6+0NjLXyDdsO2YkfE=”…
Telix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging

Telix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging

MELBOURNE, Australia, June 3, 2024 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX,…